摘要
新型ａ-受体阻断药压宁定，用于３０例ＡＳＡＩ～ Ⅱ级无明显高血压病史的全麻患者．分为对照组（不用药１０例）、用药低剂量组（０．４ｍｇ／ｋｇ，１０例）、高剂量组（０．６ｍｇ／ｋｇ，１０例），预防全麻插管及拔管时高血压反应。研究表明其降压效果明确（Ｐ＜０.０５）。下降幅度和给药前血压的高低有关。低剂量组抑制心血管应激反应作用较弱，插管与拔管期的平均压分别为１７．２和１４．４ｋＰａ。高剂量组作用明显（Ｐ＜０．０５），插管与拔管期平均压为１４．０和１１．２ｋＰａ。用药后心率较前明显增加（Ｐ＜０．０５），可能与手术前患者体液容量相对不足有关。
Urapidil (ebrantil^(R)), a new antihyperten Fsive agent with central and peripheral actions, was used for the prevention of cardiovascular reaction during intubation and extubation under general anesthesia, 30 patients (ASA ) were evenly randomized into control (without urapidil ); lower dose (0. 4 mg/kg);and higher dose groups (0. 6 mg/kg). The results showed that a significant fall of blood pressure within 1 min(P<0. 05) in the urapidil groups,and the magnitude of decrease was related to the blood pressure before treatment (mBP from 27 ~ 11mmHg ). However serious hypotension was not observed, So urapidil can be used effectively and safely in the treatment of elevated blood pressure during intubation and extubation under general anesthesia, The heart rate increased (P<O. 05) for a few minutes after urapidil administration which, probably due to compensation for the hypovolemia state of the patients.
出处
《中华麻醉学杂志》
CAS
CSCD
北大核心
1994年第2期87-89,共3页
Chinese Journal of Anesthesiology
关键词
压宁定
心血管反应
插管
拔管
麻醉
Urapidil Cardiovascular reaction Intubation Extubation
